LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Comparison of C26:0-carnitine and C26:0-lysophosphatidylcholine as diagnostic markers in dried blood spots from newborns and patients with adrenoleukodystrophy.

    Huffnagel, Irene C / van de Beek, Malu-Clair / Showers, Amanda L / Orsini, Joseph J / Klouwer, Femke C C / Dijkstra, Inge M E / Schielen, Peter C / van Lenthe, Henk / Wanders, Ronald J A / Vaz, Frédéric M / Morrissey, Mark A / Engelen, Marc / Kemp, Stephan

    Molecular genetics and metabolism

    2017  Volume 122, Issue 4, Page(s) 209–215

    Abstract: X-linked adrenoleukodystrophy (ALD) is the most common leukodystrophy with a birth incidence of 1:14,700 live births. The disease is caused by mutations in ABCD1 and characterized by very long-chain fatty acids (VLCFA) accumulation. In childhood, male ... ...

    Abstract X-linked adrenoleukodystrophy (ALD) is the most common leukodystrophy with a birth incidence of 1:14,700 live births. The disease is caused by mutations in ABCD1 and characterized by very long-chain fatty acids (VLCFA) accumulation. In childhood, male patients are at high-risk to develop adrenal insufficiency and/or cerebral demyelination. Timely diagnosis is essential. Untreated adrenal insufficiency can be life-threatening and hematopoietic stem cell transplantation is curative for cerebral ALD provided the procedure is performed in an early stage of the disease. For this reason, ALD is being added to an increasing number of newborn screening programs. ALD newborn screening involves the quantification of C26:0-lysoPC in dried blood spots which requires a dedicated method. C26:0-carnitine, that was recently identified as a potential new biomarker for ALD, has the advantage that it can be added as one more analyte to the routine analysis of amino acids and acylcarnitines already in use. The first objective of this study was a comparison of the sensitivity of C26:0-carnitine and C26:0-lysoPC in dried blood spots from control and ALD newborns both in a case-control study and in newborns included in the New York State screening program. While C26:0-lysoPC was elevated in all ALD newborns, C26:0-carnitine was elevated only in 83%. Therefore, C26:0-carnitine is not a suitable biomarker to use in ALD newborn screen. In women with ALD, plasma VLCFA analysis results in a false negative result in approximately 15-20% of cases. The second objective of this study was to compare plasma VLCFA analysis with C26:0-carnitine and C26:0-lysoPC in dried blood spots of women with ALD. Our results show that C26:0-lysoPC was elevated in dried blood spots from all women with ALD, including from those with normal plasma C26:0 levels. This shows that C26:0-lysoPC is a better and more accurate biomarker for ALD than plasma VLCFA levels. We recommend that C26:0-lysoPC be added to the routine biochemical array of diagnostic tests for peroxisomal disorders.
    MeSH term(s) ATP Binding Cassette Transporter, Sub-Family D, Member 1/genetics ; Adrenoleukodystrophy/complications ; Adrenoleukodystrophy/diagnosis ; Adrenoleukodystrophy/physiopathology ; Adult ; Biomarkers/blood ; Carnitine/analysis ; Case-Control Studies ; Cohort Studies ; Dried Blood Spot Testing/methods ; Fatty Acids/blood ; Fatty Acids/chemistry ; Fatty Acids/metabolism ; Female ; Humans ; Infant, Newborn ; Lysophosphatidylcholines/analysis ; Male ; Neonatal Screening/methods ; Netherlands ; New York ; Sensitivity and Specificity
    Chemical Substances ABCD1 protein, human ; ATP Binding Cassette Transporter, Sub-Family D, Member 1 ; Biomarkers ; Fatty Acids ; Lysophosphatidylcholines ; Carnitine (S7UI8SM58A)
    Language English
    Publishing date 2017-10-28
    Publishing country United States
    Document type Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1418518-0
    ISSN 1096-7206 ; 1096-7192
    ISSN (online) 1096-7206
    ISSN 1096-7192
    DOI 10.1016/j.ymgme.2017.10.012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Neonatal detection of Aicardi Goutières Syndrome by increased C26:0 lysophosphatidylcholine and interferon signature on newborn screening blood spots.

    Armangue, Thais / Orsini, Joseph J / Takanohashi, Asako / Gavazzi, Francesco / Conant, Alex / Ulrick, Nicole / Morrissey, Mark A / Nahhas, Norah / Helman, Guy / Gordish-Dressman, Heather / Orcesi, Simona / Tonduti, Davide / Stutterd, Chloe / van Haren, Keith / Toro, Camilo / Iglesias, Alejandro D / van der Knaap, Marjo S / Goldbach Mansky, Raphaela / Moser, Anne B /
    Jones, Richard O / Vanderver, Adeline

    Molecular genetics and metabolism

    2017  Volume 122, Issue 3, Page(s) 134–139

    Abstract: Background: Aicardi Goutières Syndrome (AGS) is a heritable interferonopathy associated with systemic autoinflammation causing interferon (IFN) elevation, central nervous system calcifications, leukodystrophy and severe neurologic sequelae. An infant ... ...

    Abstract Background: Aicardi Goutières Syndrome (AGS) is a heritable interferonopathy associated with systemic autoinflammation causing interferon (IFN) elevation, central nervous system calcifications, leukodystrophy and severe neurologic sequelae. An infant with TREX1 mutations was recently found to have abnormal C26:0 lysophosphatidylcholine (C26:0 Lyso-PC) in a newborn screening platform for X-linked adrenoleukodystrophy, prompting analysis of this analyte in retrospectively collected samples from individuals affected by AGS.
    Methods: In this study, we explored C26:0 Lyso-PC levels and IFN signatures in newborn blood spots and post-natal blood samples in 19 children with a molecular and clinical diagnosis of AGS and in the blood spots of 22 healthy newborns. We used Nanostring nCounter™ for IFN-induced gene analysis and a high-performance liquid chromatography with tandem mass spectrometry (HPLC MS/MS) newborn screening platform for C26:0 Lyso-PC analysis.
    Results: Newborn screening cards from patients across six AGS associated genes were collected, with a median disease presentation of 2months. Thirteen out of 19 (68%) children with AGS had elevations of first tier C26:0 Lyso-PC (>0.4μM), that would have resulted in a second screen being performed in a two tier screening system for X-linked adrenoleukodystrophy (X-ALD). The median (95%CI) of first tier C26:0 Lyso-PC values in AGS individuals (0.43μM [0.37-0.48]) was higher than that seen in controls (0.21μM [0.21-0.21]), but lower than X-ALD individuals (0.72μM [0.59-0.84])(p<0.001). Fourteen of 19 children had elevated expression of IFN signaling on blood cards relative to controls (Sensitivity 73.7%, 95%CI 51-88%, Specificity 95%, 95% CI 78-99%) including an individual with delayed disease presentation (36months of age). All five AGS patients with negative IFN signature at birth had RNASEH2B mutations. Consistency of agreement between IFN signature in neonatal and post-natal samples was high (0.85).
    Conclusion: This suggests that inflammatory markers in AGS can be identified in the newborn period, before symptom onset. Additionally, since C26:0 Lyso-PC screening is currently used in X-ALD newborn screening panels, clinicians should be alert to the fact that AGS infants may present as false positives during X-ALD screening.
    MeSH term(s) Autoimmune Diseases of the Nervous System/blood ; Autoimmune Diseases of the Nervous System/diagnosis ; Autoimmune Diseases of the Nervous System/genetics ; Autoimmune Diseases of the Nervous System/physiopathology ; Child, Preschool ; Chromatography, High Pressure Liquid ; Chromatography, Liquid ; Dried Blood Spot Testing/methods ; Exodeoxyribonucleases/genetics ; Female ; Humans ; Infant ; Infant, Newborn ; Inflammation/blood ; Inflammation/genetics ; Interferons/blood ; Interferons/genetics ; Lysophosphatidylcholines/blood ; Male ; Mutation ; Neonatal Screening/methods ; Nervous System Malformations/blood ; Nervous System Malformations/diagnosis ; Nervous System Malformations/genetics ; Nervous System Malformations/physiopathology ; Phosphoproteins/genetics ; Retrospective Studies ; Sensitivity and Specificity ; Tandem Mass Spectrometry ; Transcriptome/immunology
    Chemical Substances Lysophosphatidylcholines ; Phosphoproteins ; Interferons (9008-11-1) ; Exodeoxyribonucleases (EC 3.1.-) ; three prime repair exonuclease 1 (EC 3.1.16.-)
    Language English
    Publishing date 2017-07-20
    Publishing country United States
    Document type Case Reports ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1418518-0
    ISSN 1096-7206 ; 1096-7192
    ISSN (online) 1096-7206
    ISSN 1096-7192
    DOI 10.1016/j.ymgme.2017.07.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Newborn screening and early biochemical follow-up in combined methylmalonic aciduria and homocystinuria, cblC type, and utility of methionine as a secondary screening analyte.

    Weisfeld-Adams, James D / Morrissey, Mark A / Kirmse, Brian M / Salveson, Bobbie R / Wasserstein, Melissa P / McGuire, Peter J / Sunny, Sherlykutty / Cohen-Pfeffer, Jessica L / Yu, Chunli / Caggana, Michele / Diaz, George A

    Molecular genetics and metabolism

    2009  Volume 99, Issue 2, Page(s) 116–123

    Abstract: Introduction: Combined methylmalonic aciduria and homocystinuria, cobalamin C (cblC) type, is an inherited disorder of vitamin B(12) metabolism caused by mutations in MMACHC. CblC typically presents in the neonatal period with neurological deterioration, ...

    Abstract Introduction: Combined methylmalonic aciduria and homocystinuria, cobalamin C (cblC) type, is an inherited disorder of vitamin B(12) metabolism caused by mutations in MMACHC. CblC typically presents in the neonatal period with neurological deterioration, failure to thrive, cytopenias, and multisystem pathology including renal and hepatic dysfunction. Rarely, affected individuals present in adulthood with gait ataxia and cognitive decline. Treatment with hydroxocobalamin may ameliorate the clinical features of early-onset disease and prevent clinical late-onset disease. Propionic acidemia (PA), methylmalonic acidemia (MMA), and various disorders of cobalamin metabolism are characterized by elevated propionylcarnitine (C3) on newborn screening (NBS). Distinctions can be made between these disorders with secondary analyte testing. Elevated methionine is already routinely used as a NBS marker for cystathionine beta-synthase deficiency. We propose that low methionine may be useful as a secondary analyte for specific detection of cbl disorders among a larger pool of infants with elevated C3 on NBS.
    Methods: Retrospective analysis of dried blood spot (DBS) data in patients with molecularly confirmed cblC disease.
    Results: Nine out of ten patients with confirmed cblC born in New York between 2005 and 2008 had methionine below 13.4mumol/L on NBS. Elevated C3, elevated C3:C2 ratio, and low methionine were incorporated into a simple screening algorithm that can be used to improve the specificity of newborn screening programs and provide a specific and novel method of distinguishing cblC from other disorders of propionate metabolism prior to recall for confirmatory testing.
    Conclusions: It is anticipated that this algorithm will aid in early and specific detection of cobalamin C, D, and F diseases, with no additional expense to NBS laboratories screening for organic acidemias and classical homocystinuria.
    MeSH term(s) Algorithms ; Carnitine/analogs & derivatives ; Carnitine/metabolism ; Demography ; False Positive Reactions ; Female ; Follow-Up Studies ; Genetic Association Studies ; Homocystinuria/complications ; Homocystinuria/diagnosis ; Homocystinuria/genetics ; Humans ; Infant, Newborn ; Male ; Metabolism, Inborn Errors/complications ; Metabolism, Inborn Errors/diagnosis ; Metabolism, Inborn Errors/genetics ; Methionine ; Methylmalonic Acid/metabolism ; Neonatal Screening ; New York ; Propionates/metabolism ; Referral and Consultation ; Vitamin B 12/metabolism
    Chemical Substances Propionates ; acylcarnitine ; Methylmalonic Acid (8LL8S712J7) ; Methionine (AE28F7PNPL) ; propionic acid (JHU490RVYR) ; Vitamin B 12 (P6YC3EG204) ; Carnitine (S7UI8SM58A)
    Language English
    Publishing date 2009-09-27
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1418518-0
    ISSN 1096-7206 ; 1096-7192
    ISSN (online) 1096-7206
    ISSN 1096-7192
    DOI 10.1016/j.ymgme.2009.09.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Implementation of newborn screening for Krabbe disease: population study and cutoff determination.

    Orsini, Joseph J / Morrissey, Mark A / Slavin, Laura N / Wojcik, Matthew / Biski, Chad / Martin, Monica / Keutzer, Joan / Zhang, X Kate / Chuang, Wei-Lien / Elbin, Carole / Caggana, Michele

    Clinical biochemistry

    2009  Volume 42, Issue 9, Page(s) 877–884

    Abstract: Objective: The aim of this study was to develop a newborn screening algorithm for Krabbe disease.: Design and methods: We measured the galactocerebrosidase activity of 139,074 anonymous newborns, 56 known carriers, and 16 Krabbe patients using a ... ...

    Abstract Objective: The aim of this study was to develop a newborn screening algorithm for Krabbe disease.
    Design and methods: We measured the galactocerebrosidase activity of 139,074 anonymous newborns, 56 known carriers, and 16 Krabbe patients using a tandem mass spectrometry method. The activities were converted to percentages of daily mean activity (%DMA), and the results from diseased and normal populations were used to establish cutoffs.
    Results: The absolute activities for the newborns ranged from 0.17 to 355 micromol/L h (N=139,074) and activities for Krabbe-positive controls ranged from 0.08 to 0.48 micromol/L h (N=16, n=91 measurements) while activities for carriers ranged from 0.28 to 2.71 micromol/L h (N=56, n=72 measurements). Cutoffs were set based on results from Krabbe-positive and carrier controls and the newborn population distribution.
    Conclusions: The algorithm and cutoffs we propose provided 100% detection of all positive controls with 60/100,000 screen positive results predicted. In the course of this study, one anonymous newborn was predicted to have Krabbe disease based on enzyme activity and subsequent DNA analysis.
    MeSH term(s) Adolescent ; Child ; Child, Preschool ; Humans ; Infant ; Infant, Newborn ; Leukodystrophy, Globoid Cell/diagnosis ; Neonatal Screening/methods ; Reproducibility of Results ; Tandem Mass Spectrometry
    Language English
    Publishing date 2009-06
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 390372-2
    ISSN 1873-2933 ; 0009-9120
    ISSN (online) 1873-2933
    ISSN 0009-9120
    DOI 10.1016/j.clinbiochem.2009.01.022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Enhanced interpretation of newborn screening results without analyte cutoff values.

    Marquardt, Gregg / Currier, Robert / McHugh, David M S / Gavrilov, Dimitar / Magera, Mark J / Matern, Dietrich / Oglesbee, Devin / Raymond, Kimiyo / Rinaldo, Piero / Smith, Emily H / Tortorelli, Silvia / Turgeon, Coleman T / Lorey, Fred / Wilcken, Bridget / Wiley, Veronica / Greed, Lawrence C / Lewis, Barry / Boemer, François / Schoos, Roland /
    Marie, Sandrine / Vincent, Marie-Françoise / Sica, Yuri Cleverthon / Domingos, Mouseline Torquado / Al-Thihli, Khalid / Sinclair, Graham / Al-Dirbashi, Osama Y / Chakraborty, Pranesh / Dymerski, Mark / Porter, Cory / Manning, Adrienne / Seashore, Margretta R / Quesada, Jonessy / Reuben, Alejandra / Chrastina, Petr / Hornik, Petr / Atef Mandour, Iman / Atty Sharaf, Sahar Abdel / Bodamer, Olaf / Dy, Bonifacio / Torres, Jasmin / Zori, Roberto / Cheillan, David / Vianey-Saban, Christine / Ludvigson, David / Stembridge, Adrya / Bonham, Jim / Downing, Melanie / Dotsikas, Yannis / Loukas, Yannis L / Papakonstantinou, Vagelis / Zacharioudakis, Georgios S A / Baráth, Ákos / Karg, Eszter / Franzson, Leifur / Jonsson, Jon J / Breen, Nancy N / Lesko, Barbara G / Berberich, Stanton L / Turner, Kimberley / Ruoppolo, Margherita / Scolamiero, Emanuela / Antonozzi, Italo / Carducci, Claudia / Caruso, Ubaldo / Cassanello, Michela / la Marca, Giancarlo / Pasquini, Elisabetta / Di Gangi, Iole Maria / Giordano, Giuseppe / Camilot, Marta / Teofoli, Francesca / Manos, Shawn M / Peterson, Colleen K / Mayfield Gibson, Stephanie K / Sevier, Darrin W / Lee, Soo-Youn / Park, Hyung-Doo / Khneisser, Issam / Browning, Phaidra / Gulamali-Majid, Fizza / Watson, Michael S / Eaton, Roger B / Sahai, Inderneel / Ruiz, Consuelo / Torres, Rosario / Seeterlin, Mary A / Stanley, Eleanor L / Hietala, Amy / McCann, Mark / Campbell, Carlene / Hopkins, Patrick V / de Sain-Van der Velden, Monique G / Elvers, Bert / Morrissey, Mark A / Sunny, Sherlykutty / Knoll, Detlef / Webster, Dianne / Frazier, Dianne M / McClure, Julie D / Sesser, David E / Willis, Sharon A / Rocha, Hugo / Vilarinho, Laura / John, Catharine / Lim, James / Caldwell, S Graham / Tomashitis, Kathy / Castiñeiras Ramos, Daisy E / Cocho de Juan, Jose Angel / Rueda Fernández, Inmaculada / Yahyaoui Macías, Raquel / Egea-Mellado, José María / González-Gallego, Inmaculada / Delgado Pecellin, Carmen / García-Valdecasas Bermejo, Maria Sierra / Chien, Yin-Hsiu / Hwu, Wuh-Liang / Childs, Thomas / McKeever, Christine D / Tanyalcin, Tijen / Abdulrahman, Mahera / Queijo, Cecilia / Lemes, Aída / Davis, Tim / Hoffman, William / Baker, Mei / Hoffman, Gary L

    Genetics in medicine : official journal of the American College of Medical Genetics

    2012  Volume 14, Issue 7, Page(s) 648–655

    Abstract: Purpose: To improve quality of newborn screening by tandem mass spectrometry with a novel approach made possible by the collaboration of 154 laboratories in 49 countries.: Methods: A database of 767,464 results from 12,721 cases affected with 60 ... ...

    Abstract Purpose: To improve quality of newborn screening by tandem mass spectrometry with a novel approach made possible by the collaboration of 154 laboratories in 49 countries.
    Methods: A database of 767,464 results from 12,721 cases affected with 60 conditions was used to build multivariate pattern recognition software that generates tools integrating multiple clinically significant results into a single score. This score is determined by the overlap between normal and disease ranges, penetration within the disease range, differences between conditions, and weighted correction factors.
    Results: Ninety tools target either a single condition or the differential diagnosis between multiple conditions. Scores are expressed as the percentile rank among all cases with the same condition and are compared to interpretation guidelines. Retrospective evaluation of past cases suggests that these tools could have avoided at least half of 279 false-positive outcomes caused by carrier status for fatty-acid oxidation disorders and could have prevented 88% of known false-negative events.
    Conclusion: Application of this computational approach to raw data is independent from single analyte cutoff values. In Minnesota, the tools have been a major contributing factor to the sustained achievement of a false-positive rate below 0.1% and a positive predictive value above 60%.
    MeSH term(s) Computational Biology ; Data Interpretation, Statistical ; Databases, Factual ; Diagnosis, Differential ; False Positive Reactions ; Humans ; Infant, Newborn ; International Cooperation ; Metabolome ; Minnesota ; Multivariate Analysis ; Neonatal Screening/methods ; Pattern Recognition, Automated ; Predictive Value of Tests ; Retrospective Studies ; Software ; Tandem Mass Spectrometry/methods
    Language English
    Publishing date 2012-02-16
    Publishing country United States
    Document type Journal Article ; Multicenter Study ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 1455352-1
    ISSN 1530-0366 ; 1098-3600
    ISSN (online) 1530-0366
    ISSN 1098-3600
    DOI 10.1038/gim.2012.2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project.

    McHugh, David M S / Cameron, Cynthia A / Abdenur, Jose E / Abdulrahman, Mahera / Adair, Ona / Al Nuaimi, Shahira Ahmed / Åhlman, Henrik / Allen, Jennifer J / Antonozzi, Italo / Archer, Shaina / Au, Sylvia / Auray-Blais, Christiane / Baker, Mei / Bamforth, Fiona / Beckmann, Kinga / Pino, Gessi Bentz / Berberich, Stanton L / Binard, Robert / Boemer, François /
    Bonham, Jim / Breen, Nancy N / Bryant, Sandra C / Caggana, Michele / Caldwell, S Graham / Camilot, Marta / Campbell, Carlene / Carducci, Claudia / Cariappa, Rohit / Carlisle, Clover / Caruso, Ubaldo / Cassanello, Michela / Castilla, Ane Miren / Ramos, Daisy E Castiñeiras / Chakraborty, Pranesh / Chandrasekar, Ram / Ramos, Alfredo Chardon / Cheillan, David / Chien, Yin-Hsiu / Childs, Thomas A / Chrastina, Petr / Sica, Yuri Cleverthon / de Juan, Jose Angel Cocho / Colandre, Maria Elena / Espinoza, Veronica Cornejo / Corso, Gaetano / Currier, Robert / Cyr, Denis / Czuczy, Noemi / D'Apolito, Oceania / Davis, Tim / de Sain-Van der Velden, Monique G / Delgado Pecellin, Carmen / Di Gangi, Iole Maria / Di Stefano, Cristina Maria / Dotsikas, Yannis / Downing, Melanie / Downs, Stephen M / Dy, Bonifacio / Dymerski, Mark / Rueda, Inmaculada / Elvers, Bert / Eaton, Roger / Eckerd, Barbara M / El Mougy, Fatma / Eroh, Sarah / Espada, Mercedes / Evans, Catherine / Fawbush, Sandy / Fijolek, Kristel F / Fisher, Lawrence / Franzson, Leifur / Frazier, Dianne M / Garcia, Luciana R C / Bermejo, Maria Sierra García-Valdecasas / Gavrilov, Dimitar / Gerace, Rosemarie / Giordano, Giuseppe / Irazabal, Yolanda González / Greed, Lawrence C / Grier, Robert / Grycki, Elyse / Gu, Xuefan / Gulamali-Majid, Fizza / Hagar, Arthur F / Han, Lianshu / Hannon, W Harry / Haslip, Christa / Hassan, Fayza Abdelhamid / He, Miao / Hietala, Amy / Himstedt, Leslie / Hoffman, Gary L / Hoffman, William / Hoggatt, Philis / Hopkins, Patrick V / Hougaard, David M / Hughes, Kerie / Hunt, Patricia R / Hwu, Wuh-Liang / Hynes, June / Ibarra-González, Isabel / Ingham, Cindy A / Ivanova, Maria / Jacox, Ward B / John, Catharine / Johnson, John P / Jónsson, Jón J / Karg, Eszter / Kasper, David / Klopper, Brenda / Katakouzinos, Dimitris / Khneisser, Issam / Knoll, Detlef / Kobayashi, Hirinori / Koneski, Ronald / Kozich, Viktor / Kouapei, Rasoul / Kohlmueller, Dirk / Kremensky, Ivo / la Marca, Giancarlo / Lavochkin, Marcia / Lee, Soo-Youn / Lehotay, Denis C / Lemes, Aida / Lepage, Joyce / Lesko, Barbara / Lewis, Barry / Lim, Carol / Linard, Sharon / Lindner, Martin / Lloyd-Puryear, Michele A / Lorey, Fred / Loukas, Yannis L / Luedtke, Julie / Maffitt, Neil / Magee, J Fergall / Manning, Adrienne / Manos, Shawn / Marie, Sandrine / Hadachi, Sônia Marchezi / Marquardt, Gregg / Martin, Stephen J / Matern, Dietrich / Mayfield Gibson, Stephanie K / Mayne, Philip / McCallister, Tonya D / McCann, Mark / McClure, Julie / McGill, James J / McKeever, Christine D / McNeilly, Barbara / Morrissey, Mark A / Moutsatsou, Paraskevi / Mulcahy, Eleanor A / Nikoloudis, Dimitris / Norgaard-Pedersen, Bent / Oglesbee, Devin / Oltarzewski, Mariusz / Ombrone, Daniela / Ojodu, Jelili / Papakonstantinou, Vagelis / Reoyo, Sherly Pardo / Park, Hyung-Doo / Pasquali, Marzia / Pasquini, Elisabetta / Patel, Pallavi / Pass, Kenneth A / Peterson, Colleen / Pettersen, Rolf D / Pitt, James J / Poh, Sherry / Pollak, Arnold / Porter, Cory / Poston, Philip A / Price, Ricky W / Queijo, Cecilia / Quesada, Jonessy / Randell, Edward / Ranieri, Enzo / Raymond, Kimiyo / Reddic, John E / Reuben, Alejandra / Ricciardi, Charla / Rinaldo, Piero / Rivera, Jeff D / Roberts, Alicia / Rocha, Hugo / Roche, Geraldine / Greenberg, Cheryl Rochman / Mellado, José María Egea / Juan-Fita, María Jesús / Ruiz, Consuelo / Ruoppolo, Margherita / Rutledge, S Lane / Ryu, Euijung / Saban, Christine / Sahai, Inderneel / García-Blanco, Maria Isabel Salazar / Santiago-Borrero, Pedro / Schenone, Andrea / Schoos, Roland / Schweitzer, Barb / Scott, Patricia / Seashore, Margretta R / Seeterlin, Mary A / Sesser, David E / Sevier, Darrin W / Shone, Scott M / Sinclair, Graham / Skrinska, Victor A / Stanley, Eleanor L / Strovel, Erin T / Jones, April L Studinski / Sunny, Sherlykutty / Takats, Zoltan / Tanyalcin, Tijen / Teofoli, Francesca / Thompson, J Robert / Tomashitis, Kathy / Domingos, Mouseline Torquado / Torres, Jasmin / Torres, Rosario / Tortorelli, Silvia / Turi, Sandor / Turner, Kimberley / Tzanakos, Nick / Valiente, Alf G / Vallance, Hillary / Vela-Amieva, Marcela / Vilarinho, Laura / von Döbeln, Ulrika / Vincent, Marie-Francoise / Vorster, B Chris / Watson, Michael S / Webster, Dianne / Weiss, Sheila / Wilcken, Bridget / Wiley, Veronica / Williams, Sharon K / Willis, Sharon A / Woontner, Michael / Wright, Katherine / Yahyaoui, Raquel / Yamaguchi, Seiji / Yssel, Melissa / Zakowicz, Wendy M

    Genetics in medicine : official journal of the American College of Medical Genetics

    2011  Volume 13, Issue 3, Page(s) 230–254

    Abstract: Purpose: To achieve clinical validation of cutoff values for newborn screening by tandem mass spectrometry through a worldwide collaborative effort.: Methods: Cumulative percentiles of amino acids and acylcarnitines in dried blood spots of ... ...

    Abstract Purpose: To achieve clinical validation of cutoff values for newborn screening by tandem mass spectrometry through a worldwide collaborative effort.
    Methods: Cumulative percentiles of amino acids and acylcarnitines in dried blood spots of approximately 25–30 million normal newborns and 10,742 deidentified true positive cases are compared to assign clinical significance, which is achieved when the median of a disorder range is, and usually markedly outside, either the 99th or the 1st percentile of the normal population. The cutoff target ranges of analytes and ratios are then defined as the interval between selected percentiles of the two populations. When overlaps occur, adjustments are made to maximize sensitivity and specificity taking all available factors into consideration.
    Results: As of December 1, 2010, 130 sites in 45 countries have uploaded a total of 25,114 percentile data points, 565,232 analyte results of true positive cases with 64 conditions, and 5,341 cutoff values. The average rate of submission of true positive cases between December 1, 2008, and December 1, 2010, was 5.1 cases/day. This cumulative evidence generated 91 high and 23 low cutoff target ranges. The overall proportion of cutoff values within the respective target range was 42% (2,269/5,341).
    Conclusion: An unprecedented level of cooperation and collaboration has allowed the objective definition of cutoff target ranges for 114 markers to be applied to newborn screening of rare metabolic disorders.
    MeSH term(s) Amino Acids/blood ; Carnitine/analogs & derivatives ; Carnitine/blood ; Humans ; Infant, Newborn ; International Cooperation ; Metabolic Diseases/diagnosis ; Neonatal Screening ; Reference Values ; Sensitivity and Specificity ; Software ; Tandem Mass Spectrometry
    Chemical Substances Amino Acids ; acylcarnitine ; Carnitine (S7UI8SM58A)
    Language English
    Publishing date 2011-02-08
    Publishing country United States
    Document type Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S. ; Validation Study
    ZDB-ID 1455352-1
    ISSN 1530-0366 ; 1098-3600
    ISSN (online) 1530-0366
    ISSN 1098-3600
    DOI 10.1097/GIM.0b013e31820d5e67
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top